Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
  2. Our Websites |
  3. Global Business Websites |
  4. Contact Us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce Increase  


Contact Us

sanofi-aventis (Malaysia) Sdn. Bhd. (334110-P)

Unit TB-18-1, Level 18
Tower B, Plaza 33
No.1 Jalan Kemajuan, Seksyen 13
46200 Petaling Jaya

Tel : +603 7651 0800
Fax: +603 7651 0801/2

Content :


Thrombosis affects both the arterial (Atherothrombosis) and venous (Venous Thromboembolism) systems.


Venous Thromboembolism (VTE)

Venous Thromboembolism (VTE), which is the obstruction of a vein by a blood clot, is the third most common cardiovascular disease in the western world, occurring in about 0.1% of people every year. The most common manifestation of VTE is deep venous thrombosis (DVT) which occurs when a clot forms in the deep veins of the lower limbs. This is a common condition in elderly ill patients who are bedridden, post-surgical patients who are immobilised for a period of time as well as in patients who undergo major surgical and orthopaedic procedures. It can also occur in patients who have a genetic condition predisposing to abnormal clotting of blood. The most serious consequence of a DVT is pulmonary embolism (PE). This occurs when the clot (or pieces of) dislodges and moves to the lungs and causes a blockage to the blood vessels of the lungs. PEs are serious and carry a significant fatality rate. sanofi-aventis produces the leading low molecular weight heparin that has been proven in numerous clinical trials to prevent and treat of VTE.

Atherothrombosis (AT)

Atherothrombosis (AT) occurs when a blood clot forms on fatty deposits in the wall of a blood vessel. It is a dangerous condition because if the clot grows and completely blocks an affected artery, blood stops flowing and the tissue downstream to the blockage is at risk, sometimes with life-threatening consequences. If AT occurs in the arteries of the heart, a blockage leads to Acute Coronary Syndromes (ACS) or heart attacks. Similarly, if it occurs in the arteries supplying the brain, ischemic strokes (IS) occur. Peripheral arterial disease (PAD) occurs when AT affects the arteries of the lower limbs. AT is increasingly common due to our modern lifestyles. With advancing medical knowledge and therapies, patients who are at high risk of developing atherothrombosis can be identified and managed accordingly. sanofi-aventis produces the leading anti-platelet agent that has also been proven by numerous clinical trials to treat and prevent recurrent AT events.

Updated August 28, 2009

Module :